| Title |
Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
|
|---|---|
| Published in |
Breast Cancer Research, April 2014
|
| DOI | 10.1186/bcr3640 |
| Pubmed ID | |
| Authors |
Haiyu Zhang, Adam L Cohen, Sujatha Krishnakumar, Irene L Wapnir, Selvaraju Veeriah, Glenn Deng, Marc A Coram, Caroline M Piskun, Teri A Longacre, Michael Herrler, Daniel O Frimannsson, Melinda L Telli, Frederick M Dirbas, AC Matin, Shanaz H Dairkee, Banafshe Larijani, Gennadi V Glinsky, Andrea H Bild, Stefanie S Jeffrey |
| Abstract |
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. Phosphatidylinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are frequently activated in TNBC patient tumors at the genome, gene expression and protein levels, and mTOR inhibitors have been shown to inhibit growth in TNBC cell lines. We describe a panel of patient-derived xenografts representing multiple TNBC subtypes and use them to test preclinical drug efficacy of two mTOR inhibitors, sirolimus (rapamycin) and temsirolimus (CCI-779). |
Mendeley readers
The data shown below were compiled from readership statistics for 119 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Germany | 1 | <1% |
| Unknown | 117 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 20% |
| Student > Ph. D. Student | 20 | 17% |
| Student > Master | 13 | 11% |
| Student > Bachelor | 8 | 7% |
| Student > Doctoral Student | 7 | 6% |
| Other | 19 | 16% |
| Unknown | 28 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 25 | 21% |
| Biochemistry, Genetics and Molecular Biology | 21 | 18% |
| Medicine and Dentistry | 20 | 17% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 6% |
| Computer Science | 2 | 2% |
| Other | 12 | 10% |
| Unknown | 32 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2014.
All research outputs
#22,759,802
of 25,374,647 outputs
Outputs from Breast Cancer Research
#1,883
of 2,053 outputs
Outputs of similar age
#209,715
of 241,188 outputs
Outputs of similar age from Breast Cancer Research
#27
of 29 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,188 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.